Large-Scale Mass Spectrometry Imaging Investigation of Consequences of Cortical Spreading Depression in a Transgenic Mouse Model of Migraine by unknown
B The Author(s), 2015. This article is published with open access at Springerlink.com
DOI: 10.1007/s13361-015-1136-8
J. Am. Soc. Mass Spectrom. (2015) 26:853Y861
FOCUS: IMAGING MASS SPECTROMETRY: RESEARCH ARTICLE
Large-Scale Mass Spectrometry Imaging Investigation
of Consequences of Cortical Spreading Depression
in a Transgenic Mouse Model of Migraine
Ricardo J. Carreira,1 Reinald Shyti,2 Benjamin Balluff,1 Walid M. Abdelmoula,3
Sandra H. van Heiningen,2 Rene J. van Zeijl,1 Jouke Dijkstra,3 Michel D. Ferrari,4
Else A. Tolner,4 Liam A. McDonnell,1,5 Arn M. J. M. van den Maagdenberg2,4
1Center for Proteomics and Metabolomics, Leiden University Medical Center, Einthovenweg 20, 2333 ZCLeiden, The Netherlands
2Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
3Division of Image Processing, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
4Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands
5Fondazione Pisana per la Scienza ONLUS, Pisa, Italy
WT R192Q 
Increasing CSD severity Abstract. Cortical spreading depression (CSD) is the electrophysiological correlate
of migraine aura. Transgenic mice carrying the R192Q missense mutation in the
Cacna1a gene, which in patients causes familial hemiplegic migraine type 1 (FHM1),
exhibit increased propensity to CSD. Herein, mass spectrometry imaging (MSI) was
applied for the first time to an animal cohort of transgenic and wild type mice to study
the biomolecular changes following CSD in the brain. Ninety-six coronal brain sec-
tions from 32mice were analyzed byMALDI-MSI. All MSI datasets were registered to
the Allen Brain Atlas reference atlas of the mouse brain so that the molecular
signatures of distinct brain regions could be compared. A number of metabolites
and peptides showed substantial changes in the brain associated with CSD. Among
those, different mass spectral features showed significant (t-test, P < 0.05) changes in the cortex, 146 and
377 Da, and in the thalamus, 1820 and 1834 Da, of the CSD-affected hemisphere of FHM1 R192Q mice. Our
findings reveal CSD- and genotype-specific molecular changes in the brain of FHM1 transgenic mice that may
further our understanding about the role of CSD in migraine pathophysiology. The results also demonstrate the
utility of aligning MSI datasets to a common reference atlas for large-scale MSI investigations.
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Introduction
Matrix-assisted laser desorption/ionization (MALDI) massspectrometry imaging (MSI) is a label-free technique
capable of analyzing hundreds of biomolecular ions directly
from tissue in a spatially correlated manner [1]. Main factors
contributing to the increasing popularity of this technology
include the ability to (1) analyze a large range of molecular
classes (proteins, peptides, lipids, metabolites, pharmaceuticals);
(2) reveal disease-related biomolecular changes in highly local-
ized regions; and (3) unravel changes that are invisible to
established histopathological methods [2–4].
MSI has been applied to a multitude of tissues from various
tumor tissues [5, 6] to plant tissues [7], but rodent brain [8, 9] is
still the most frequently analyzed tissue type because of its
widespread availability and use in neurologic research [10].
For instance, MALDI-MSI has been used to visualize spatio-
temporal disturbances in rodent models of seizure [11], stroke
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[12], Alzheimer’s disease [13, 14], and Parkinson’s disease
[15–17]. These studies demonstrate the potential of MSI for
neurologic research, and which have been further validated by
studies using small animal cohorts [8]. The application ofMSI to
preclinical investigations of neurologic disorders requires con-
siderable multidisciplinary capabilities: MSI, statistics, and
knowledge of brain anatomy. The latter aspect is exacerbated
by the high degree of variation in brain region size that exists
between animals [18] and the variability introduced during tissue
sectioning and mounting. We recently demonstrated how MSI
data could be automatically aligned to the Allen Brain Atlas,
which allows the analyst to ensure all tissue sections of animals
are obtained from a similar region of the mouse brain and to
extract the mass spectral signatures from identical brain regions
[19]. Here, we demonstrate how this registration pipeline en-
ables larger-scale preclinical investigations of neurologic disor-
ders. This first demonstration of such a cohort studied and
analyzed by MSI concerns migraine.
Migraine is a common, severe episodic brain disorder that is
characterized by attacks of severe unilateral throbbing headache
associated with nausea, vomiting, photo- and phonophobia
[20, 21]. An aura, which consists of transient neurologic symp-
toms, including visual and sensory disturbances, can accompany
a migraine attack in one-third of patients. The aura is caused by
cortical spreading depression (CSD), a slow, self-propagating
wave of neuronal and glial cell depolarization in the cerebral
cortex of one hemisphere followed by neuronal depression
[22–24]. CSD causes a temporary dramatic failure of brain
homeostasis, efflux of neurotransmitters, and changes in metab-
olism. Several metabolites, such as labile phosphate compounds
(ATP, ADP, AMP, their cyclic analogues, cGMP, and phospho-
creatine) and glycolytic metabolites (lactate, pyruvate, glucose,
and glycogen) have been associated with CSD [25].
In 2012, Jones et al. [26] reported a proof-of-concept
MALDI-MSI investigation of the biomolecular changes in
C57BL/6 J wild-type (WT) mouse brain following CSD. The
study included 2D- and 3D-MSI datasets, including an exclu-
sion matrix to highlight apparent CSD-related changes, but
omitted any form of statistical analysis because of the small
number of animals involved in the study. Accordingly, the
results obtained provided limited information regarding the
biological aspects and changes associated with CSD. Here we
report, for the first time, the application of MSI to a large scale
animal cohort of a neurologic disease, in particular CSD as the
neurobiologic correlate of the migraine aura. To this end, we
make use of a relevant mouse model of migraine (i.e., knock-in
transgenic mice carrying the pathogenic human R192Q mis-
sense mutation in theCacna1a gene that encodes the α1 subunit
of voltage-gated neuronal CaV2.1 Ca
2+ channels [27, 28]).
CaV2.1 Ca
2+ channels with a R912Q-mutated α1 subunit cause
familial hemiplegicmigraine type 1 (FHM1) [29], a monogenic
subtype of migraine with aura characterized by a prominent
transient hemiparesis during the aura [20]. FHM1 R192Q mice
exhibit an increased propensity to CSD, most likely because of
an enhanced glutamatergic neurotransmission [27, 28, 30, 31].
In addition, unlike in WT mice, CSD waves can reach
subcortical areas in R192Q mice, which correlate with the
clinical phenotype [32]. We hypothesized that CSD could
induce the expression of different biomolecular profiles in the
brains of R192Q mice compared with wild-type. We measured
and compared the biomolecular profiles of both mouse strains
at specific cortical and subcortical brain regions and were able




Male 2- to 4-month-old transgenic FHM1 R192Q mice (carry-
ing the human pathogenic missense mutation R192Q) and
corresponding non-transgenic wild-type (WT) mice were used.
Transgenic mice were generated by introducing the human
pathogenic mutation in the mouse Cacna1a gene using a gene
targeting approach, as described in [27]. All mice were kept in a
normal 12:12 light/dark regime and food and water were avail-
able ad libitum. The 32 animals used in this study were divided
into different groups according to the experimental conditions:
WT-Naïve (five animals); WT-Sham (six animals); WT-CSD
(five animals); R192Q-Naïve (five animals); R192Q-Sham
(six animals); R192Q-CSD (five animals). All experiments
were approved by the Animal Experiment Ethics Committee of
Leiden University Medical Center.
CSD Experiments
CSD experiments were performed as previously described [26].
In brief, the mice were anesthetized with 4% isoflurane in
pressurized air (21% O2 and 79% N2) and mounted on a
stereotactic frame (David Kopf, Tujunga, CA, USA); 1.5%
isoflurane was used for maintenance of the anesthesia. A mid-
line incision was made to expose the skull. Two burr holes were
drilled over the following coordinates (from bregma): 0.5 mm
anterior, 2 mm lateral for DC recordings, and 3.5 mm posterior,
2 mm lateral for KCl or NaCl application. Seven CSDs were
induced by applying a cotton ball soaked in 1 M KCl (CSD) or
NaCl (Sham) for 30 s followed by extensive saline washing.
The interval between two successive applications was 5 min.
DC-potential signals were measured with respect to an Ag/AgCl
reference electrode placed subcutaneously in the neck and
amplified 10× (Molecular Devices, Sunnyvale, CA, USA).
The DC signal was low-pass filtered at 4 Hz and digitized at
100–200 Hz using PowerLab 16/30 hardware (AD Instruments,
Inc., Colorado Springs, CO, USA). Data were recorded and
analyzed off-line using LabChart Pro (AD Instruments).
Sample Collection and Tissue Preparation
Following seven CSD/Sham events, the mice were decapitated
5 min after the last CSD/Sham event, the brains quickly re-
moved (within <2 min), immediately snap-frozen on powdered
dry ice, and stored at –80°C until further processing. Coronal
tissue sections, 12-μm thick, were cut at –12°C using a cryostat
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microtome (Leica Microsystems, Wetzlar, Germany), thaw-
mounted onto poly-L-lysine coated indium-tin-oxide (ITO)
glass slides (Bruker Daltonics, Bremen, Germany), and stored
at –80°C. In order to exclude the effect of electrode insertion
and KCl or NaCl application, only sections from the middle
part of the brain (posterior from bregma, in between locations –
1.22 and –1.94 mm) were used for MSI analysis. For the
selection of sections in this part of the brain, the brain was
trimmed in 25 μm slices and individual sections were visually
inspected under a microscope and compared with the Paxinos
Mouse Brain Atlas reference (3rd Edition; ISBN 978-0-12-
374244-5) to judge their location along the anteroposterior
axis, based on histologic landmarks. Once the level corre-
sponding to the location –1.22 posterior from bregma was
reached, 12 μm thick coronal sections were collected for the
MSI experiments. For each animal, consecutive tissue sections
were collected on different ITO slides for the analysis of
proteins, peptides, and metabolites. Each ITO slide contained
tissue sections from four animals. A semi-supervised block
randomization was used to distribute the sections in a random
way across and within slides while maximizing the group
heterogeneity within a slide. This included the position of each
sample on theMALDI slides and themeasurement order within
a slide—in order to minimize any potential sources of bias
during MSI data acquisition (see Supplementary Information
for the pseudo-code).
Mass Spectrometry Imaging
Tissue sections were collected from storage at –80°C and
equilibrated to room temperature (RT, 23°C) for 30 min in a
vacuum desiccator. The slides were prepared for MALDI-MSI
according to the molecular class to be analyzed. For peptide
and protein imaging the tissue sections were washed as fol-
lows: (1) dip in 70% ethanol for 30 s; (2) dip in 96% ethanol for
30 s; (3) five short dips in deionized water; (4) dip in 70%
ethanol for 30 s; (5) dip in 96% ethanol for 30 s; and finally (6)
dried in a vacuum desiccator for 15min. Nowashing procedure
was applied to the samples used for the analysis of metabolites.
MALDI matrix was uniformly applied over the brain sections
using the SunCollect sprayer (SunChrom, Friedrichsdorf,
Germany) according to the analyzed molecular class:
sinapinic acid (SA; 5 mg/mL in 50% acetonitrile/0.3% TFA)
was used for proteins; α-cyano-4-hydroxycinnamic acid
(CHCA; 5 mg/mL in 50% acetonitrile/ 0.3% TFA) was used
for peptides; and 9-aminoacridine (9AA; saturated solution in
70% methanol) was used for metabolites. MSI analyses of
peptides (600–2000 Da) and metabolites (50–1000 Da) were
performed using an UltrafleXtreme MALDI-TOF/TOF
(Bruker Daltonics) in the reflectron positive (for peptides) or
negative (for metabolites) ion mode with 100 μm raster width,
500 laser shots per pixel. MSI of proteins (3000–20,000 Da)
was performed in an Autoflex III MALDI-TOF (Bruker
Daltonics) in the linear positive ion mode with 100 μm raster
width, 500 laser shots per pixel. Data acquisition, preprocess-
ing, and visualization were performed using the flex software
package from Bruker Daltonics: flexImaging 3.0 was used for
experiment definition; flexControl 3.4 was used for data acqui-
sition; and flexAnalysis 3.4 was used for on-the-fly mass spec-
tral processing—metabolite/peptide datasets were preprocessed
using a Gauss smoothing algorithm (width 0.02m/z, 2 cycles)
and a TopHat baseline subtraction algorithm; protein MSI
spectra were preprocessed identically except the parameters of
the Gauss smoothing algorithm were adapted for the lower
mass resolution (width 2m/z, 4 cycles).
After the MSI experiments, the matrix was washed off
with 70% ethanol and the tissue samples stained with cresyl
violet (Nissl staining). High-resolution histologic images
were recorded using a Pannoramic MIDI digital slide scanner
(3D Histech, Budapest, Hungary).
Processing and Reduction of MSI Datasets
High-resolution histologic images were co-registered to the
MSI data with flexImaging using fiducial markers applied at
defined positions on each ITO slide with water-based correc-
tion fluid (Tipp-Ex; Ecolutions, BIC, Clichy, France) before
MSI analyses. A list of all mass spectra contained within each
brain section was extracted into an XML file for further pro-
cessing inMATLABR2011a (MathWorks, Natick, MA, USA).
The preprocessed mass spectra contained in the MSI datasets
were then read into Matlab.
Metabolite Datasets The spectra were normalized to their
total-ion-count (TIC) on a pixel-by-pixel basis and aligned on
common peaks that are present in at least 85% of the samples.
Peak picking and feature extraction was performed using the
global base peak mass spectrum [33]. Briefly, this routine
distils the original MSI data into an image cube containing
the spatial distribution of every detected peak. Finally, a
logarithmic-based variance-stabilizing transformation was ap-
plied to the peak intensities in order to reduce the impact of
Poisson noise in the datasets [34, 35].
Peptide and Protein Datasets Except for the logarithmic trans-
formation of peak intensities, which was not performed for these
datasets, all processing steps were as described above including
TIC normalization on a pixel-by-pixel basis, with minor modifi-
cations in the thresholds used for peak picking to account for the
different characteristics of the peptide and protein datasets.
Image Processing and Registration to the Mouse
Allen Brain Atlas
The reduced MSI datasets and the aligned histologic
images were registered to the mouse Allen Brain Atlas (ABA);
http://www.brain-map.org/) using our recently developed pipe-
line [19]. In brief, the histologic images are first preprocessed to
reduce background noise and acquisition artifacts. Then the
ABA corresponding histologic image is selected based on the
maximum cord length of the hippocampus. Image registration is
performed by applying a rigid affine transformation (correct for
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translation, shearing, rotation, and scaling), followed by nonlin-
ear registration based on a B-Spline transform (correct for local
deformations). Finally, the transformationmatrix used to register
the sample and ABA histologic images is applied to the respec-
tive MSI datasets.
Anatomy Driven Data Analysis
The anatomic annotations contained in the ABA were used to
define four anatomical regions of interest (ROI) in the MSI
datasets: cortex (C), striatum (S), hippocampus (H), and thala-
mus (T). MS data were extracted from each ROI from every
ABA-aligned MSI dataset for statistical analysis: (1) a non-
paired Student’s t-test was used for comparisons between in-
dependent groups; and (2) a paired Student’s t-test was used for
comparisons (left versus right hemispheres) within each inde-
pendent group of animals. The Benjamini-Hochberg procedure
was used to correct for multiple testing. All statistical analyses
were done in R (R Foundation for Statistical Computing,
Vienna, Austria) and Matlab, in which P-values < 0.05 were
considered statistically significant.
Results
CSD Induction and MSI Analysis
Seven CSD events were evoked, each with a 5 min interval in
the occipital cortex of WT and transgenic FHM1 R192Q mice;
equivalent Sham experiments utilizing aqueous NaCl instead
of aqueous KCl, which does not evoke a CSD, were performed
in parallel so as to clearly differentiate CSD-related from non-
CSD-related biomolecular changes. As shown in Table S1
(Supplementary Information), there were no significant dif-
ferences between R192Q and WT mice regarding the CSD
characteristics and time under anesthesia. All animals were
sacrificed 5 min after the last CSD event and the brains
were immediately removed and frozen on dry ice to limit
post-mortem degradation effects. Previous studies have in-
dicated that the analysis of metabolites can be significantly
impaired by post-mortem degradation [36–38]. These re-
sults indicated that labile metabolites, such as AMP,
ADP, and ATP that act as energy reserves in the brain
can be used as a measure of the post-mortem degradation
effects. We measured the AMP/ATP ratios across the dif-
ferent mouse brains but found no correlation with the short
post-mortem times of these experiments, which indicated
that any variability associated with the isolation of the
mouse brain had a negligible effect on the MSI data.
Alignment of MSI Datasets to a Single Reference
System
Preclinical studies typically compare a number of animals per
test group to guard against the individual variation in any
animal population. We have analyzed a total of 96 mouse brain
sections from 32 animals from 16 R192Q and 16WTmice. We
registered all histologic images and MSI datasets to the mouse
brain reference atlas contained within the Allen Brain Atlas
[19] in order to (1) reduce the impact of variance attributable to
differences in brain region size [18]; (2) check if all tissue
sections came from a similar region of the brain; and (3) correct
for any tissue-processing artifacts introduced during the exper-
iment (e.g. ,folds, tears). The 96 brain sections were registered
to just 3 of 132 different coronal sections present in the ABA
reference atlas, corresponding to a tissue-section sampling
accuracy between animals of 200 μm, and thus indicating we
sampled similar regions of the mouse brain. The registration
itself was performed with an accuracy of less than 30 μm,
which is below the spatial resolution used for the MSI mea-
surements (100 μm) (see Figure 5, reference [19]). A scheme of
the workflow is presented in Figure 1.
Anatomy Based Data Analysis
The distribution of proteins, peptides, and metabolites after
CSD and Sham operations was investigated across the whole
brain and in four particular brain regions that are of relevance to
migraine pathophysiology [32]: cortex, striatum, hippocampus,
and thalamus. Electrophysiology measurements indicate that
when induced in one hemisphere, CSD does not cross to the
other hemisphere [30, 39]; accordingly, the left (unaffected)
hemisphere was used as control for the CSD/Sham-affected
right hemisphere.
Protein Datasets Comparison between right (CSD-affected)
and left (control) hemispheres within the R192Q-CSD group
revealed moderate differences in the distribution of m/z feature
11,302 Da and statistically significant differences in the distribu-
tion of m/z feature 11,344 Da (P < 0.05, Student’s t-test), as
shown in Figure 2. In both cases, the ion intensities are lower in
the CSD-affected hemisphere (R). These changes were not ob-
served in the WT and Sham groups. Poté et al. [40] have
previously identified the same molecular features as histone H4
and respective acetylated form while analyzing hepatocellular
carcinoma. Although their experiment concerned human tissue
samples, a Basic Local Alignment Search Tool (BLAST) search
(in UniProt database) revealed 100% homology with murine
histone H4.
Peptide Datasets Intra-group comparison between right
(CSD-affected) and left (control) hemispheres showed signifi-
cant differences occurring in the thalamus region for m/z fea-
tures 1819.96 Da and 1833.96 Da (P < 0.05, Student’s t-test)
only in R192Q-CSD mice (Figure 3). A decrease in ion inten-
sities was observed in the CSD-affected brain hemisphere in
both cases. Similarly to the protein dataset, also these
biomolecular features share the same spatial distribution
and are separated by 14 Da, which is compatible with a
methylation post-translational modification. Moderate dif-
ferences were also observed in the R192Q mouse brains
after CSD, in particular m/z 1713.8 with increased ex-
pression in the cortex of the CSD-affected hemisphere,
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and m/z 1754.85 and its K+ adduct m/z 1792.85 with
decreased expression in the striatum of the CSD hemisphere.
No significant biomolecular changes were observed for the
Sham and Naïve mouse groups.
Metabolite Datasets Intra-group comparisons between con-
trol and CSD-affected hemispheres revealed differences asso-
ciated with CSD in WT and R192Q mice (Supplementary
Information, Figure S1). Biomolecular features present at
89.03 Da showed an increase in signal intensity in the CSD-
affected hemisphere, whereas m/z features at 146.07 Da,
339.01 Da, 360.97 Da, and 376.97 Da presented a decrease
in intensity in the CSD-affected hemisphere. Interestingly,
significant changes were only found in the distribution of two
m/z features for R192Q-CSD mice (P < 0.05, Student’s t-test),
particularlym/z 146.07Da and 376.97Da as shown in Figure 4.
In order to more confidently assign the m/z features observed,
we performed high-resolution MS analysis by MALDI Fourier
transform ion cyclotron resonance (FTICR) directly from
tissue. Accurate masses were then searched in the metabo-
lite database METLIN revealing the presence of glutamate
([M – H]– 146.0459 Da), fructose 1,6-bisphosphate ([M – H]–
338.9888 Da), and fructose 1,6-bisphosphate K+ adduct
([M + K – 2H]– 376.9447 Da) among other isobaric species.
Discussion
MSI is a non-targeted methodology that allows the analysis of
different biomolecular classes directly from tissue. One of the
main advantages of MSI is its ability to unravel biomolecular
Figure 1. Schematic of workflow developed to analyze the effect of CSD inWT and R192Qmouse brains. Ninety-six coronal brain
sections were obtained from a total of 32 mouse brains (three consecutive sections per animal). Proteins, peptides, andmetabolites
were independently analyzed by MSI using optimized sample treatment for each molecular class as described in the Materials and
Methods section. Each sectionwas stainedwith Nissl reagent aftermatrix removal and theMSI datasets, and histologic imageswere
aligned to the Allen Brain Atlas of mouse brain [19]. Automatic anatomical annotation of regions of interest allowed the extraction of
MSI data from specific brain regions of interest and statistical analysis
Figure 2. ProteinMSI dataset: differences betweenCSD (right, R) and control hemisphere (left, L) in R192Q-CSDmouse brain. Each
image corresponds to the visualization of the average distribution of a particularm/z feature in fivemouse brains after alignment to the
ABA (*P < 0.05, Student’s t-test). C = cortex; T = thalamus; H = hippocampus; S = Striatum
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changes independently of histology. This is of particular inter-
est to the study of migraine, a neurologic disorder characterized
by recurrent attacks and lack of clear histopathologic features.
Many metabolites, amino acids, and neuropeptides have been
measured in the brain during and after CSD experiments [25].
However, the effects of CSD are still not fully understood,
namely: (1) How are the proteome, peptidome, and metabo-
lome profiles affected by CSD? (2) How are the CSD changes
affected by the genetic background of the mice (i.e., a compar-
ison between mice with a genetic predisposition to migraine
Figure 3. Peptide MSI dataset: differences between CSD (right, R) and control hemisphere (left, L) in R192Q-CSD mouse brain.
Each image corresponds to the visualization of the average distribution of a particularm/z feature in five mouse brains after alignment
to the ABA (*P < 0.05, Student’s t-test). C = cortex; T = thalamus; H = hippocampus; S = striatum
Figure 4. Metabolite MSI dataset: differences between CSD (right, R) and control hemisphere (left, L) in R192Q-CSD mouse brain.
Each image corresponds to the visualization of the average distribution of a particularm/z feature in five mouse brains after alignment
to the ABA (*P < 0.05, Student’s t-test). C = cortex; T = thalamus; H = hippocampus; S = striatum
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and wild-type mice)? (3) Does CSD induce biomolecular
changes in subcortical areas? To answer these questions, we
measured and compared the biomolecular profiles of FHM1
R192Q and WT mice after CSD induction in the occipital
cortex.
The biomolecular profiles recorded by MSI presented dis-
turbances that may be associated with the CSD wave progres-
sion only in R192Qmouse brain. Given the short time between
CSD induction and animal sacrifice, ca. 40 min after the first
CSD event, significant changes in protein expression level
were not expected. Indeed, the only significant change revealed
by MSI is associated with a post-translational modification in
histone H4: acetylated histone H4 (11,344 Da) showed a de-
creased intensity in the cortical region of the CSD-affected
hemisphere. Likewise, previous reports showed that CSD in-
duction in rats affected methylation levels in the cortex, al-
though this was evident 24 h following CSD induction [41, 42].
Histone modifications such as acetylation, methylation,
ubiquitination, and phosphorylation have an important role in
the epigenetic regulation of transcription and have been asso-
ciated with neurologic diseases such as Alzheimer's disease,
Huntington’s disease, and Parkinson’s disease [43]. Therefore,
the effect of CSD on post-translational modification of histones
and, consequently, on the transcription mechanisms, may have
relevance to migraine.
It is well known that CSD triggers the release of vasoactive
peptides [44, 45]. Trigeminal axons that innervate the dural
vessels and are activated during CSD release calcitonin gene
related peptide (CGRP), Substance P (SP), and neurokinin-α
(NKA), which all are potent vasodilators [45–49]. These vaso-
active peptides are believed to be mediators of neurogenic
inflammation, which is thought to be a mechanism relevant to
the generation of migraine headache [48, 49]. Interestingly,
levels of CGRP and SP in the blood of migraine patients were
found increased between and during attacks [50–52]. Although
we did not observe significant changes in any of these com-
pounds, the MSI peptide datasets revealed moderate differ-
ences in the distributions of a few biomolecular features
(1392.75 Da; 1713.80 Da; 1754.85 Da; 1871.88 Da) in mouse
brain hemispheres affected by CSD, which is in agreement
with the idea that CSD induction triggers a substantial redistri-
bution of peptides in the extracellular space. Additionally, a
significant decrease in the intensity ofm/z features 1819.96 and
1833.92 Da was observed only in the thalamus region of
R192Q mice. Although the identity of these m/z features is
currently unknown, their similar distribution and m/z shift
consistent with a methylation post-translational modification
indicate that these may be different forms of the same peptide.
In the peptide datasets, we detected changes in subcortical
regions (striatum and thalamus) as a result of CSD. This is in
agreement with previously published data indicating that CSD
induction in the cortex may also easily spread to subcortical
regions in FHM1 R192Q but not in wild-type mice [32].
Therefore, the differential distribution of peptides in the stria-
tum, thalamus, and hippocampus identified after CSD might
reflect a subcortical spread of CSD waves. Yet, the possibility
for a transport of peptides released in the cortex to subcortical
structures cannot be excluded at this time.
Several metabolites such as ATP, ADP, AMP, cGMP,
lactate, pyruvate, glucose, and glycogen have been associated
with CSD [25]. In addition, CSD can also trigger the release of
amino acids and change their brain regional distribution. Dur-
ing single episodes of CSD in rat brain, interstitial levels of
several amino acids (e.g., alanine, arginine, aspartate, gluta-
mate, glycine) were found to be elevated, highlighting the
massive changes in biomolecular distribution that occur in the
brain during episodes of CSD [53]. Our MSI metabolite
datasets revealed a significant decrease in the intensity of m/z
feature 146.07 in the cortical region of R192Q mice after CSD.
Owing to the high number of isobaric molecules in this mass
region, it is virtually impossible to identify small metabolites
directly from tissue with MS/MS analysis. Yet, after high-
resolution MS analysis and assignment based on previous
reports, this biomolecule was assigned as glutamate. Glutamate
plays a major role in CSD, and elevated levels of glutamate and
glutamic acids have been detected in plasma [54] and cerebro-
spinal fluid (CSF) [55, 56] of migraine patients. Of note,
pharmacologic targeting of glutamate receptors is currently
being explored as a potential migraine therapy [57]. Glutamate
is a well-known trigger of CSD [58], and during CSD propa-
gation in the cortex there is a release of glutamate to the
extracellular space [53, 59]. Given the above, the down-
regulation of glutamate in cortex of CSD-affected brain hemi-
spheres observed by MSI analysis may seem contradictory, at
first. Previous quantitative proteomics studies in naïve FHM1
R192Q mice, however, revealed an up-regulation of major
glutamate transporters, EAAT1 and EAAT2, compared with
WT mice [60]. These findings, together with the MSI results
reported here, suggest that a compensatory mechanism in the
brain might be in place to clear excessive glutamate from the
synaptic space by glial cells using glutamate transporters.
Besides the putative identification of glutamate changes, our
MSI data revealed significant differences in the spatial locali-
zation of m/z 376.96 Da in the R192Q brain after CSD. Data-
base search based on high-resolution MS indicated that this
molecular feature is probably associated with different forms of
fructose 1,6-biphosphate, which is a byproduct of fructose and
glucose metabolism common to all cells. In a previous publi-
cation, this m/z feature was also assigned as fructose 1,6-
bisphospate by MSI in a rat model of ischemic stroke [12].
Interestingly, the distribution of fructose 1,6-biphosphate and
glutamate in the ischemic brain is similar to the distribution
observed after CSD in both R192Q and WT mice. Recently
Eikermann-Haerter et al. [61] studied the link between stroke
and migraine using the same transgenic FHM1 R192Q mice
and demonstrated that FHM mutations do not only enhance
susceptibility to CSD but also to ischemic depolarizations,
leading to stroke. Therefore, the MSI results reported here
in combination with previous work by Miura et al. [12]
seem to suggest that there is indeed a link between CSD
and stroke events, although more work is required to prove
this hypothesis.
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Conclusions
Here we used MALDI-MSI combined with a newly developed
pipeline that allows the automatic registration ofMS datasets to
mouse data contained in the Allen Brain Atlas [19], to inves-
tigate the biomolecular distribution in the brain after CSD in a
relevant mouse model of migraine. Our results revealed that
CSD events affect the distribution of metabolites, peptides and
proteins, not only in the cortex but also in subcortical struc-
tures. The finding that changes in biomolecules distribution
were only evident in R192Q mice that had undergone CSD
indicates that these changes are both genotype- and CSD-
specific. Future work should reveal the identities of biomole-
cules that are affected by CSD events and might provide more
in-depth insights in migraine pathophysiology. In conclusion,
our results show that CSD induction in FHM1 R192Q mice is
associated with a substantial redistribution of biomolecules in
the brain and highlight that MALDI-MSI can be instrumental
in preclinical animal models of disease.
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